IL15 and B-cell chronic lymphocytic leukemia: Rapid and impressive responses (ORR: 73% CR: 64%) were achieved with a bicistronic CD19-28-ζ CAR/IL-15 UCB NK cells in chronic lymphocytic leukemia (CLL) and lymphoma refractory and relapsed setting (NCT03056339).